ArticleMolecular oncology2011
NFIB is a potential target for estrogen receptor-negative breast cancers.
Article in Molecular oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 57 citations in OpenAlex.
- Altered microRNA profiles and associated pathways in canine mammary adenocarcinoma.Scientific reports · 2025Article
- LINC01235 Is an Upstream Regulator of the NFIB Gene and the Notch Pathway in Triple-Negative Breast Cancer.Molecular cancer research : MCR · 2025Article
- Molecular pathology of adenoid cystic carcinoma.Histology and histopathology · 2025Review
- Biological mechanisms and clinical significance of endoplasmic reticulum oxidoreductase 1 alpha (ERO1α) in human cancer.Journal of experimental & clinical cancer research : CR · 2024Review
- NFIB facilitates replication licensing by acting as a genome organizer.Nature communications · 2023Article
- The NFIB/CARM1 partnership is a driver in preclinical models of small cell lung cancer.Nature communications · 2023Article
- Article
- Circ_0069718 promotes the progression of breast cancer by up-regulating NFIB through sequestering miR-590-5p.Mammalian genome : official journal of the International Mammalian Genome Society · 2021Article
- Predicting master transcription factors from pan-cancer expression data.Science advances · 2021Article
- The NFIB-ERO1A axis promotes breast cancer metastatic colonization of disseminated tumour cells.EMBO molecular medicine · 2021Article
- CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation.Oncogene · 2021Article
- Nuclear factor I/B mediates epithelial-mesenchymal transition in human melanoma cells through ZEB1.Oncology letters · 2021Article
- Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.Breast cancer research : BCR · 2020Article
- MicroRNA-138-5p targets the NFIB-Snail1 axis to inhibit colorectal cancer cell migration and chemoresistance.Cancer cell international · 2020Article
- Nuclear factor I/B promotes colorectal cancer cell proliferation, epithelial-mesenchymal transition and 5-fluorouracil resistance.Cancer science · 2019Article
- Prognostic significance of NFIA and NFIB in esophageal squamous carcinoma and esophagogastric junction adenocarcinoma.Cancer medicine · 2018Article
- ERα Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signaling to Modulate Estrogen Responsiveness in Breast Cancer.Cancer research · 2018Article
- hsa-miR-301a- and SOX10-dependent miRNA-TF-mRNA regulatory circuits in breast cancer.Turkish journal of biology = Turk biyoloji dergisi · 2018Article
- Nuclear Factor I/B: A Master Regulator of Cell Differentiation with Paradoxical Roles in Cancer.EBioMedicine · 2017Review
- NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.EBioMedicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe association between nuclear factor I/B (NFIB) gene and triple negative breast cancer has been previously suggested.
methodsWe investigated the relationship between NFIB mRNA and protein expression and molecular subtypes of breast cancer as well as the effect of NFIB silencing on the proliferation and apoptosis of breast cancer cells. Also, the clinical importance of NFIB expression was investigated in 163 breast cancer patients.
resultsBy using 20 frozen human breast cancer tissues and various breast cancer cell lines, we observed a significant high level of NFIB mRNA level in triple negative breast cancer. NFIB protein was upregulated in ER negative breast cancer tissues but the expression level was similar between HER2 subtype and triple negative subtype. The clinical significance of NFIB was further examined in a tissue microarray from 163 invasive breast cancer patients, and the immunohistochemistry results showed a significant association between NFIB expression and nuclear grade, ER, and HER2 expression status. NFIB positive tumors were more likely to have high nuclear grade, ER negativity and HER2 over-expression. HCC1954 cells transfected with siRNA against NFIB showed a significant reduction in cell proliferation and increase in apoptotic signaling pathway.
conclusionsOur results show a potential role of NFIB as a novel target in ER negative breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.